Takeda expects limited commercial impact from Actos actions
This article was originally published in Scrip
Good domestic growth, cost savings from restructuring in the US and a lower effective tax rate all helped Takeda's bottom line in the first quarter to 30 June, when group net profit rose by 18% to ¥75.6 billion ($971.7 million; ¥95.75 per share).
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.